PPARγ agonists inhibit release of pro-inflammatory cytokine IL-6 in monocytes.29 IL-6 elicits survival response in glioma cells through STAT3.26 As heightened STAT3 activation promotes glioma progression, STAT3 inhibitors are regarded as a potential therapeutic target for glioma.6 Depletion of pSTAT3 on CIDEA overexpression possibly prevents IL-6 from exhibiting its pro-survival response despite increase in its levels. The gene discussed is PPARG; the disease is central nervous system cancer.